Answers are grounded in this paper and cite their sources.
This non-interventional, active safety surveillance study conducted signal detection/evaluation analyses for the primary series, monovalent booster doses, and Omicron BA.4/BA.5-adapted bivalent booster dose of the Pfizer-BioNTech COVID-19 vaccine among Veterans Health Administration (VHA) enrollees. Repeated longitudinal, cohort study analyses using data from the VHA Corporate Data Warehouse were conducted. Among individuals who received ≥1 Pfizer-BioNTech COVID-19 vaccination between 12/11/2020–06/30/2023, an active comparator design was used to monitor the occurrence of 48 safety events of interest in this population compared to individuals with seasonal influenza vaccines during the 2014/2015–2018/2019 influenza seasons. In addition, a self-controlled risk interval design was used to compare the occurrence of safety events of interest during post-vaccination risk versus control intervals among individuals experiencing the safety event of interest. The Pfizer-BioNTech COVID-19 vaccine sample comprised 1,652,514 individuals, the majority of whom were male (89.8%) with an average age of 64.0 years (median = 67.4); it included 59.7% White non-Hispanic and 22.0% Black individuals. The seasonal influenza vaccine sample included 4,104,220 individuals, and baseline demographic and clinical characteristics were generally similar between the Pfizer-BioNTech COVID-19 and seasonal influenza vaccine samples (standardized differences<10%). After signal detection analyses, further investigation was warranted for cerebrovascular non hemorrhagic stroke, other acute demyelinating disease, Guillain-Barré syndrome, anaphylaxis, acute myocardial infarction, arrhythmia, coronary artery disease, myocarditis, stress cardiomyopathy, microangiopathy, chilblain-like lesions, hemorrhagic disease, pulmonary embolism, optic neuritis, heart failure and cardiogenic shock, acute kidney injury, deep vein thrombosis, and severe COVID-19 disease. However, no safety events remained after signal evaluation analysis (including for myocarditis/pericarditis), regardless of the vaccine dose. There was no increased risk of any of the 48 safety events of interest evaluated following Pfizer-BioNTech COVID-19 vaccination in the VHA population.
No takes yet. Share an insight, caveat, or question.
Asomaning et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: